Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
BörsenkürzelGCTK
Name des UnternehmensGlucoTrack Inc
IPO-datumApr 09, 2013
Gegründet am2010
CEOMr. Paul V. Goode, Ph.D.
Anzahl der mitarbeiter11
WertpapierartOrdinary Share
GeschäftsjahresendeApr 09
Addresse301 Rt 17 North
StadtRUTHERFORD
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl07070
Telefon197286757878
Website
BörsenkürzelGCTK
IPO-datumApr 09, 2013
Gegründet am2010
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten